Twitter

Biostock: Otto Skolling elected to Chordate Medical’s Board

In a new interview, Biostock talk with Otto Skolling, who was recently elected Vice Chairman of the Board of Chordate Medical. Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry.

“I am quite new to the company, so it is likely that I do not yet see all the opportunities and potential that the company has. However, it is clear to everyone that a new treatment in migraine for all those patients who do not respond to existing drugs, and it is a large group, with an effect on par with the best is of course very exciting. Here I believe that Chordate has an opportunity to become a serious alternative for those who today do not respond to existing drugs or who do not want to use these heavy drugs that are associated with today’s migraine treatment”, says Otto Skolling to Biostock.

Read the full interview

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter